India continues to carry one of the highest burdens of multidrug-resistant tuberculosis (MDR/RR-TB) globally, making treatment innovation a public health priority. Recent findings from an ICMR-supported evaluation indicate that six-month, all-oral regimens such as BPaL (Bedaquiline, Pretomanid, Linezolid) offer a clinically effective and cost-efficient alternative to traditional 9–18 month injectable-based therapies. The reduced duration not only improves patient convenience but also significantly enhances treatment completion rates.
Conventional longer regimens have historically been associated with higher default rates, prolonged toxicity exposure, and complications such as ototoxicity from injectables. In contrast, shorter all-oral regimens reduce pill burden over time, minimize serious adverse events linked to injectable agents, and allow quicker functional recovery factors that…
